Iberia Pharmaceuticals India Ltd.
NSE & BSETBA
TBA
1 Shares
TBA
₹10
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 9,653.7 | 8,672.1 | |
| 171.36 | 44 | |
| 9,825.06 | 8,716.1 | |
| 7,951.2 | 6,434.59 | |
| 1,515.22 | 1,954.21 | |
| 1,113.49 | 1,419.13 |
Subscription Details
IPO Timeline
IPO Offer Start
TBA
IPO Offer Ends
TBA
TBA
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Capital expenditure towards the procurement of plant & machinery for the | 348.951 |
| 2 | Repayment of all or a portion of certain outstanding borrowings availed by our | 120 |
| 3 | Branding and marketing expenses towards enhancing the awareness and | 169 |
| 4 | Funding the working capital requirements of our Company | 310 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
97.59%
Promoter stake
Offered to Public
64,75,560
shares
IPO Registrar
Bigshare Services Pvt Ltd
About the Company
We are an Indian pharmaceutical and derma cosmetics company with a select portfolio of products across aesthetic dermatology, hair care, cardio diabetic and general therapeutics, offering solutions for a wide range of skin, hair, cardiovascular, diabetic and anti-aging concerns. Our products comprise pharmaceutical products, including drugs requiring prescriptions from healthcare professionals, as well as derma cosmetic products and other over-thecounter solutions for healthcare and aesthetic use. India’s aesthetic dermatology market has become one of the fastest-expanding sectors in healthcare and beauty. Valued at USD 620 million in CY25, it is projected to reach USD 1,274 Million by CY31, driven by increasing awareness of skin health, societal shifts, and the growing popularity of minimally invasive treatments. Once considered a niche, aesthetic dermatology is now widely accepted across diverse demographics, including millennials and men.
Use of Proceeds
1. Capital expenditure towards the procurement of machinery for the establishment of our manufacturing facility in Haryana, India 2. Repayment of all or a portion of certain outstanding borrowings availed by our Company. 3. Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand; 4. Funding the working capital requirements of our Company; 5. General Corporate Purposes.
Iberia Pharmaceuticals India Ltd. Latest News
News
No news found for Iberia Pharmaceuticals India Ltd..
IPO FAQs
The for the Iberia Pharmaceuticals India Ltd. IPO is 1 shares, which is also the minimum order quantity — you have to apply for at least 1 shares, and in multiples of 1 beyond that.
Bigshare Services Pvt Ltd is the for the Iberia Pharmaceuticals India Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them.
Iberia Pharmaceuticals India Ltd. IPO shares are proposed to be listed on BSE and NSE.
Each Iberia Pharmaceuticals India Ltd. share has a of ₹10.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 97.59% of Iberia Pharmaceuticals India Ltd. before the IPO.
64,75,560 shares of Iberia Pharmaceuticals India Ltd. are being offered to the public in this issue.
- 1.Capital expenditure towards the procurement of machinery for the establishment of our manufacturing facility in Haryana, India
- 2.Repayment of all or a portion of certain outstanding borrowings availed by our Company
- 3.Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand
- 4.Funding the working capital requirements of our Company
- 5.General Corporate Purposes
Turnaround Corporate Advisors Pvt Ltd. is the book running lead manager for the Iberia Pharmaceuticals India Ltd. IPO.
Pre-apply means placing your Iberia Pharmaceuticals India Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Iberia Pharmaceuticals India Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Iberia Pharmaceuticals India Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.